Therefore, the change in the drug's half-life period when applied in vivo is closely related to the dose, and it is necessary to conduct in vivo or clinical experiments to find a suitable drug dose and administration frequency for patients with FLT3-ITD / FLT3-ITD relapsed or refractory AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.